Share-based Payment Arrangement, Expense of REVIVA PHARMACEUTICALS HOLDINGS, INC. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
REVIVA PHARMACEUTICALS HOLDINGS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • REVIVA PHARMACEUTICALS HOLDINGS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $458,379, a 32% increase year-over-year.
  • REVIVA PHARMACEUTICALS HOLDINGS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,326,992, a 59% increase year-over-year.
  • REVIVA PHARMACEUTICALS HOLDINGS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $1,630,341, a 52% decline from 2023.
  • REVIVA PHARMACEUTICALS HOLDINGS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $3,413,354, a 1831% increase from 2022.
  • REVIVA PHARMACEUTICALS HOLDINGS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $176,735, a 66% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

REVIVA PHARMACEUTICALS HOLDINGS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,326,992 $458,379 +$110,323 +32% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $2,216,669 $395,277 +$36,284 +10% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $2,180,385 $919,119 +$550,044 +149% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $1,630,341 $554,217 +$163,619 +42% 01 Oct 2024 31 Dec 2024 10-K 03 Apr 2025 2024 FY
Q3 2024 $1,466,722 $348,056 -$2,354 -0.67% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $1,469,076 $358,993 -$2,261,826 -86% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $3,730,902 $369,075 +$317,548 +616% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $3,413,354 $390,598 +$334,012 +590% 01 Oct 2023 31 Dec 2023 10-K 03 Apr 2025 2024 FY
Q3 2023 $3,079,342 $350,410 +$309,823 +763% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $2,769,519 $2,620,819 +$2,580,943 +6472% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $188,576 $51,527 +$11,841 +30% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $176,735 $56,586 -$5,448 -8.8% 01 Oct 2022 31 Dec 2022 10-K 15 Apr 2024 2023 FY
Q3 2022 $182,183 $40,587 +$12,997 +47% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $169,186 $39,876 +$22,787 +133% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $146,399 $39,686 +$39,686 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $106,713 $62,034 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $27,590 +$27,590 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $17,089 +$17,089 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $0 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $0 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $0 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2

REVIVA PHARMACEUTICALS HOLDINGS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,630,341 -$1,783,013 -52% 01 Jan 2024 31 Dec 2024 10-K 03 Apr 2025 2024 FY
2023 $3,413,354 +$3,236,619 +1831% 01 Jan 2023 31 Dec 2023 10-K 03 Apr 2025 2024 FY
2022 $176,735 +$70,022 +66% 01 Jan 2022 31 Dec 2022 10-K 15 Apr 2024 2023 FY
2021 $106,713 +$106,713 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $0 $0 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $0 01 Jan 2019 31 Dec 2019 10-K/A 07 May 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.